文献速递肾移植

早期亚临床炎症在监测性肾移植活检中的长期免疫学结局

Long-term immunological outcomes of early subclinical inflammation on surveillance kidney allograft biopsies.
PubMed 文献 · Kidney Int · 2022-08-29

本研究为前瞻性观察队列,纳入2013至2017年在本中心连续接受肾移植的1000例患者,其中586例在移植后第一年内接受监测性活检并纳入分析。中位随访五年发现,亚临床炎症伴肾小管炎(SCI-T)组后续临床活检证实的急性排斥反应调整比值比为3.8(2.1-7.5),死亡删失移植物丢失调整风险比为1.99(1.04-3.84),均显著高于无显著炎症(NSI)组。

要点

  • 移植后第一年内监测性活检发现的亚临床炎症(SCI)预示后续免疫学事件。
  • SCI-T组后续临床活检证实的急性排斥反应调整比值比为3.8(2.1-7.5),显著高于NSI组。
  • SCI-T组死亡删失移植物丢失调整风险比为1.99(1.04-3.84),显著高于NSI组。

核心结论

  • 移植后第一年内通过监测性活检发现的亚临床炎症是后续免疫学事件的预兆,与后续临床活检证实的急性排斥反应和死亡删失移植物丢失的显著更高风险相关。
  • 作者认为研究凸显了通过监测性活检识别亚临床炎症患者并制定策略预防进一步同种免疫损伤的必要性。

研究设计与样本

  • 前瞻性观察队列,纳入2013至2017年在本中心连续接受肾移植的1000例患者。
  • 排除临床排斥反应及无法进行监测性活检的患者后,纳入586例在移植后第一年内接受监测性活检的患者。
  • 根据活检发现分组:282例无显著炎症(NSI),304例亚临床炎症伴肾小管炎(SCI-T),其中182例亚临床交界性改变(SC-BLR)、122例亚临床T细胞介导排斥反应(SC-TCMR,Banff 2019分类1A或以上)。
  • 中位随访五年,追踪临床活检证实的急性排斥反应(C-BPAR)、长期肾功能和死亡删失移植物丢失。

主要发现

  • 临床活检证实的急性排斥反应事件在移植后中位两年时被记录到。
  • SCI-T组(SC-BLR和SC-TCMR)后续发生临床活检证实的急性排斥反应的调整比值比为3.8(2.1-7.5),显著高于NSI组。
  • SCI-T组死亡删失移植物丢失的调整风险比为1.99(1.04-3.84),显著高于NSI组。

临床怎么用

  • 作者认为研究凸显了通过监测性活检识别亚临床炎症患者并制定策略预防进一步同种免疫损伤的必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The long-term impact of early subclinical inflammation (SCI) through surveillance biopsy has not been well studied. To do this, we recruited a prospective observational cohort that included 1000 sequential patients who received a kidney transplant from 2013-2017 at our center. A total of 586 patients who underwent a surveillance biopsy in their first year post-transplant were included after excluding those with clinical rejections, and those who were unable to undergo a surveillance biopsy. Patients were classified based on their biopsy findings: 282 with NSI (No Significant Inflammation) and 304 with SCI-T (SCI and Tubulitis) which was further subdivided into 182 with SC-BLR (Subclinical Borderline Changes) and 122 with SC-TCMR (Subclinical T Cell Mediated Rejection, Banff 2019 classification of 1A or more). We followed the clinical and immunological events including Clinical Biopsy Proven Acute Rejection [C-BPAR], long-term kidney function and death-censored graft loss over a median follow-up of five years. Episodes of C-BPAR were noted at a median of two years post-transplant. Adjusted odds of having a subsequent C-BPAR was significantly higher in the SCI-T group [SC-BLR and SC-TCMR] compared to NSI 3.8 (2.1-7.5). The adjusted hazard for death-censored graft loss was significantly higher with SCI-T compared to NSI [1.99 (1.04-3.84)]. Overall, SCI detected through surveillance biopsy within the first year post-transplant is a harbinger for subsequent immunological events and is associated with a significantly greater hazard for subsequent C-BPAR and death-censored graft loss. Thus, our study highlights the need for identifying patients with SCI through surveillance biopsy and develop strategies to prevent further alloimmune injuries.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Mehta RB, Melgarejo I, Viswanathan V, et al. Long-term immunological outcomes of early subclinical inflammation on surveillance kidney allograft biopsies. Kidney Int. 2022. PMID: 36049641. doi:10.1016/j.kint.2022.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。